Lykan Bioscience Collaborates with Vineti to Take Cell-Based Therapies from the Clinic to the Market

Lykan Bioscience's world-class manufacturing capabilities, combined with Vineti's premier digital enterprise platform for cell and gene therapy supply chains, will streamline process development and manufacture, enabling these therapies to be delivered to patients in need.

FREMONT, CA: Lykan Bioscience, contract development and manufacturing organization (CDMO) specializing in cell-based therapies, and Vineti, the world's only enterprise software platform dedicated to supplying chain orchestration for clinical and commercial cell therapies, partners that will combine Lykan's purpose-built cell therapy manufacturing capabilities with Vineti's industry-leading supply chain and data management capabilities. The collaboration enables biopharma customers to benefit from an increased manufacturing efficiency and a comprehensive solution for delivering cell-based, life-saving treatments to patients in need.

Advanced medicines, such as cell therapies, necessitate the development of sophisticated infrastructure. The legacy processes for manufacturing cell treatments are frequently manual and outdated, impeding scalability, speed, and patient safety during development. The cell treatment industry requires a new degree of transparency, detail, and accessibility across all products and facilities in the supply chain. Lykan and Vinetis' global, non-exclusive relationship will enable Chain of Identity (COI) and Chain of Custody (COC) visibility throughout the manufacturing supply chain, focusing on patient safety.

“At Lykan, our mission is to be an innovative manufacturer of cell therapy products. We strive to help our biopharma partners achieve a rapid transition from clinical to commercial manufacturing and maximize patient access to cell therapies. The complex nature of cell therapy process development and manufacturing means our partners need innovative technologies, a reliable platform and strong manufacturing expertise to deliver safe and effective therapies,” says Lykan President and CEO Patrick Lucy.

 “Our strategic partnership with Vineti aims to enable our partners’ success with faster and simpler operations using a more robust and traceable control system.”

Lykan Bioscience has created a world-class, purpose-built production facility for various cell therapy products outside Boston, Massachusetts. Lykan will be able to conduct real-time monitoring of the manufacturing process and product, complete with electronic batch records that support real-time testing and release of the product, using advanced and integrated software systems, such as the Vinetis Personalized Therapy Management® (PTM) platform, a proven purpose-built, enterprise-grade digital solution for advanced therapy data and supply chains.

“Cell therapies are at a point where they require a truly world-class, purpose-built, multi-product cell therapy manufacturing facility, with the best digital tools, allowing for true connectivity across the ecosystem,’ says Vineti CEO and Co-founder Amy DuRoss. “We are thrilled to partner with Lykan Bioscience to ensure COI and COC visibility as therapies go through each step in the supply chain, to efficiently deliver these therapies to the patients that need them faster."

This collaboration follows Lykan's recent announcement of the appointment of a new Chief Technology Officer and Vinetis introduction of its PTM Essentials solution for clinical-stage advanced therapeutics. Both companies' business development teams can provide additional information on the Lykan-Vineti solution.